Davis Polk advised Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc., including coordinating all international regulatory filings.  The acquisition was completed following the receipt of regulatory approval from all government authorities required by the merger agreement, including an “exhaustive, 10-month investigation” by the Federal Trade Commission of the parties’ treatments and potential treatments for hemophilia A.  See Statement of the Federal Trade Commission, In re Roche Holding/Spark Therapeutics, Commission Matter No. 1910086, December 16, 2019.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.  Spark Therapeutics, based in Philadelphia, Pennsylvania, is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. See Roche to Complete $4.3 Billion Spark Deal as Regulators Give All Clear, Reuters, December 16, 2019.

The Davis Polk team advising Roche was led by partners Ronan P. Harty and Jesse Solomon.

Copy link to share post